^
Association details:
Biomarker:HER-2 V777L
Cancer:Colorectal Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Excerpt:
Five HER2 mutations were tested in NCI-H508 cells, and all mutations produced resistance to cetuximab and panitumumab. Cetuximab inhibited the growth of NCI-H508 parental cells (Supplementary Fig. S2A), whereas NCI-H508–HER2V777L and HER2WT cells grew in the presence of cetuximab.
DOI:
10.1158/2159-8290.CD-14-1211